CRISPR-like technique offers clues to mimic protective genetic mutations
Using a variation of CRISPR gene editing may be a potential strategy for mimicking the protective effects of a genetic mutation linked to lower cholesterol levels and heart disease risks, according to new mouse research from the Perelman School of Medicine at the University of Pennsylvania published this week in Circulation.
People with naturally occurring mutations that cause a loss of function in the gene for ANGPTL3 have reduced blood triglycerides, LDL cholesterol, and risk of coronary heart disease, with no apparent detrimental consequences to their health. This makes the ANGPTL3 protein an attractive target for new heart disease drugs. Earlier studies at Penn found that single copies of inactivating mutations in ANGPTL3 are found in about one in every 250 people of European heritage; however, people with mutations in both copies of the gene are more rare.
A team led by Kiran Musunuru, MD, PhD, MPH, an associate professor of Cardiovascular Medicine, assessed in a mouse model whether base editing – a variation of CRISPR genome editing that does not require breaks in the double-strand of DNA – might be used in humans one day to introduce mutations into ANGPTL3 to reduce blood lipid levels.
“This proof-of-principle study showed that base-editing of ANGPTL3 is a potential way to permanently treat patients with harmful blood lipid levels,” Musunuru said. “It would be especially useful in patients with a rare condition called homozygous familial hypercholesterolemia, which causes sky-high cholesterol levels and dramatically increased risk of heart attack. They are very difficult to treat with today’s medications, and a one-time CRISPR ‘vaccination’ might be ready to use in these patients within five years.”
The study took a three-part approach. First, the team injected normal mice with the base-editing treatment for the ANGPTL3 gene. After a week, sequencing of the ANGPTL3 target site in liver samples from the mice revealed a median 35 percent editing rate in the target gene and no off-target mutations. In addition, the mean levels of blood lipids were significantly lower in the treated mice by up to 30 percent compared to untreated mice.
Second, the researchers compared mice with the modified ANGPTL3 gene to those injected with a base-editing treatment for another liver gene, PCSK9, for plasma cholesterol and triglycerides. After a week, ANGPTL3 targeting caused a similar reduction in cholesterol but a much greater decline in triglycerides compared to targeting PCSK9. The PCSK9 protein is the target of currently available medications, including evinacumab, which has been shown to reduce cholesterol (but not triglycerides) as well as the risk of heart attack and stroke.
Third, they looked at how base editing of the ANGPTL3 gene performed in a mouse model of homozygous familial hypercholesterolemia (in which knocking out PCSK9 had little effect). After two weeks, the treated mice showed substantially reduced triglycerides (56 percent) and cholesterol (51 percent) compared to untreated mice.
Musunuru’s lab is now preparing to test CRISPR-based treatments against the human ANGPTL3 gene in human liver cells transplanted into mice. This will provide important information on efficacy and safety that will be needed before human trials can move forward.
Learn more: Gene-editing Reduces Triglycerides, Cholesterol by Up to 50 Percent, Finds Penn Animal Study
The Latest on: Gene editing
[google_news title=”” keyword=”Gene editing” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Gene editing
- Prime Medicine gets green light for trials of first-ever prime editing drugon May 1, 2024 at 1:33 am
Prime Medicine has received the first-ever IND from the FDA for a prime editing drug which it is investigating in chronic granulomatous.
- Invest In A Revolutionary Gene Therapy With CRISPR Therapeuticson April 30, 2024 at 10:25 am
CRISPR Therapeutics' Casgevy could generate significant shareholder value if proven to be successful. Learn why I am highly bullish on CRSP stock.
- Prime Medicine Gets FDA Okay for First Trial of Gene Editing Techniqueon April 30, 2024 at 8:27 am
The FDA has cleared a clinical trial of an ex vivo prime editing candidate in patients with a rare disease, Prime Medicine announced Monday. The technique taps CRISPR technology to rewrite defective ...
- Boosting crop colors with gene editing can improve weed controlon April 30, 2024 at 1:53 am
At the heart of this progressive strategy lies the concept of modifying the composition of crops with gene editing ...
- Gene seekers discover atypical genes that control multiple valuable soybean traitson April 30, 2024 at 1:27 am
A team led by Purdue University soybean geneticist Jianxin Ma has developed a new biotechnological tool for the domestication of desirable traits from wild soybeans, such as resistance to leafhopper ...
- FDA Clears Prime Medicine’s IND for First Prime Editing Therapyon April 29, 2024 at 5:00 pm
“We are thrilled to achieve this important milestone for our first product candidate, PM359, which represents the first-ever IND clearance for a Prime Editor product candidate and a significant ...
- CRISPR-Cas Gene Editing Help Combat Antimicrobial Resistanceon April 29, 2024 at 11:08 am
Despite rising global antimicrobial resistance (AMR), researchers highlight CRISPR/Cas systems' potential in antimicrobial agent development.
- Generative AI arrives in the gene editing world of CRISPRon April 29, 2024 at 6:00 am
Much like ChatGPT generates poetry, a new AI system devises blueprints for microscopic mechanisms that can edit your DNA.
- ‘ChatGPT for CRISPR’ creates new gene-editing toolson April 28, 2024 at 5:00 pm
This week, researchers published details of how they used a generative AI tool called a protein language model — a neural network trained on millions of protein sequences — to design CRISPR ...
- Regeneron to collaborate on gene editing therapies with Doudna-founded Mammothon April 25, 2024 at 7:10 am
Regeneron Pharmaceuticals and Mammoth Biosciences will collaborate to research, develop and commercialize gene editing therapies for multiple diseases, the companies said on Thursday.
via Bing News